Models to study thrombotic disorders

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 667-671

  Badimon, Lina ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ARTERY THROMBOSIS; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CONFERENCE PAPER; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TRANSGENIC ANIMAL; VEIN THROMBOSIS;

EID: 0030756926     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657609     Document Type: Conference Paper

References (63)

1. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Thrombosis in Cardiovascular Disorders. Fuster V, Verstraete M, eds. W. B. Saunders Company, Philadelphia, PA 1992; pp 17-39.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992; 326: (Part I) 242-50. (Part II) 310-8.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992; 326: (Part I) 242-50. (Part II) 310-8.
4. Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86: III74-85.
5. Fuster V, Ip JH, Badimon L, Badimon JJ, Stein B, Chesebro JH. Importance of experimental models for the development of clinical trials on thromboatherosclerosis. Circulation 1991; 83: IV15-25.
6. Fuster V, Badimon L, Badimon JJ, Ip JH, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clin Proc 1991; 66: 818-31.
7. Badimon L, Badimon JJ. Interaction of Platelet Activation and Coagulation. In: Atherosclerosis and Coronary Artery Disease. Fuster V, Ross R, Topol EJ, eds. Lippincott-Raven Publishers, Philadelphia, Pennsylvania 1996; pp 639-56.
8. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994; 24: 1091-4.
9. Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23,7: 1562-9.
10. Hirsh J, Salzman EW, Raider VJ, Colman RW. Therapeutics agents and their practical use in thrombotic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. 3rd J. B Lippincott Company, Philadelphia, PA 1994.
11. Beimond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-60.
12. Hirsh J, Salzman EW. Pathogenesis of Venous Thromboembolism. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J. B. Lippincott Company, Philadelphia, PA 1987; 1199-207.
13. Carmeliet P, Collen D. Gene Targeting and Gene Transfer Studies of the Biological Role of the Plasminogen/Plasmin System. Thromb Haemostasis 1995; 74: 429-36.
14. Powell J, Clozel J, Muller R, Kuhn H, Hefti F, Hosang M, Baumgartner H. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
15. MERCATOR Study Group. Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?. Circulation 1992; 86: 100-10.
16. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide AII receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 1991; 49: PL223-8.
17. Prescott M, Webb R, Reidy MA. Angiotensin-converting enzyme inhibitors versus angiotensin II, AT1 receptor antagonist: Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991; 139: 1291-302.
18. Schwartz SM, Reidy MA, O'Brien ERM. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemostasis 1995; 74: 541-51.
19. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-20.
20. Rand JH, Badimon L, Gordon RE, Uson RR, Fuster V. Distribution of von Willebrand Factor in porcine intima varies with blood vessel type and location. Arteriosclerosis 1987; 7: 287-91.
21. 111 labeled platelets on collagen, subendothelium and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
22. Pueyo C, Badimon JJ, Royo T, Feigen LP, Badimon L. A mimetic of the RGDF-peptide (arginine-glycine-aspartic acid-phenylanine) blocks aggregation and flow-induced thrombosis on severely injured stenotic arterial wall. Effects on different animal models and in humans. Thromb Res 1996; 81: 101-12.
23. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M, Read MS, Bailliart O, Koch GG, Vaiman M, Brinkhous KM, Pignaud GA, Sigman JL, Griggs TR, Drouet L. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: Effect on arterial thrombosis in chimeras. P Natl Acad Sci USA 1995; 92: 2455-9.
24. Turitto VT, Weiss HJ, Baumgartner HR, Badimon L, Fuster V. Cells and aggregates at surfaces. Ann NY Acad Sci 1987; 516: 453-67.
25. Weiss HJ. Flow-Related platelet deposition on subendothelium. Thromb Haemostasis 1995; 74: 117-22.
26. Adams PC, Lam JYT, Badimon L, Chesebro JH, Fuster V. Interactions of platelets and vessel wall in the development of restenosis after coronary angioplasty. Ann NY Acad Sci 1987; 516: 605-20.
27. Heras M, Chesebro JH, Webster M, Mruk J, Grill D, Badimon L, Fuster V. Prevention of thrombosis by recombinant hirudin during arterial angioplasty in pigs : Comparison with heparin. J Am Coll Cardiol 1989; 13: 77A.
28. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. P Natl Acad Sci USA 1989; 86: 8412-6.
29. Badimon L, Badimon JJ, Rand J, Turitto VT, Fuster V. Platelet deposition on von Willebrand Factor deficient vessels extra-corporeal perfusion studies in swine with von Willebrand's disease using native and heparinized blood. J Lab Clin Med 1987; 110: 634-47.
30. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in non-parallel streamlines. Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
31. Cadroy Y, Maraganore JM, Hanson SR, Harker LA. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. P Natl Acad Sci USA 1991; 88: 1177-81.
32. Lam JYT, Chesebro JH, Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 1987; 75: 243-8.
33. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr., Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-12.
34. Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-Arg CH2Clin baboons. Blood 1993; 81: 1762-70.
35. Sawa H, Fujii S, Sobel BE. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-15.
36. Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemostasis, 1993; 70: 111-18.
37. Mailhac A, Badimon JJ, Fallon JT, Fernández-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-96.
38. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall, and isolated collagen type I at arterial flow conditions in a porcine model : Effects hirudins, heparin and calcium chelation. Blood 1991; 78: 423-34.
39. Harsfalvi J, Stassen JM, Hoylaerts MF, Van Houtte E, Sawyer RT, Vermylen J, Deckmyn H. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood 1995; 85 (3): 705-11
40. Meyer BJ, Badimon JJ, Mailhac A, Fernández-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus : targeting optimal therapy. Circulation 1994; 90: 2432-8.
41. Kotze HF, Badenhorst PN, Lamprecht S, Meiring M, Van-Wyk V, Nuyts K, Stassen JM, Vermylen J, Deckmyn H. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb Haemostasis 1995; 74 (2): 751-757.
42. 111-platelet accumulation compared with thermal laser angioplasty. J Am Coll Cardiol 1990; 16: 502-6.
43. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. Laser Surg Med 1994; 14: 7-12.
44. Meyer BJ, Fernández-Ortiz A, Mailhac A, Falk E, Badimon L, Don Michael A, Chesebro JH, Fuster V, Badimon JJ. Local delivery of r-hirudin by a double balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994; 90: 2474-80.
45. Badimon L, Alfon J, Royo T, Berrozpe M, Martínez-González J, Vidal F, Chesebro JH, Fuster V, Badimon JJ. Cell biology of restenosis post-angioplasty. Z Kardiol 1995; 84 (Supp4): 145-9.
46. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73: 797-807.
47. Folts JD. Inhibition of platelet function in vivo or in vitro by organic nitrates. J Am Coll Cardiol 1991; 18: 1537-8.
48. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
49. Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Matthyssens G, Nystrom A, Vermylen J. Characterization of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. Thromb Haemost 1995; 74 (2): 655-9.
50. Deckmyn H, Stassen JM, Vreys I, Van-Houtte E, Sawyer RT, Vermylen J. Calin from Hirudo medicinalis, and inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood 1995; 85 (3): 712-9.
51. Golino P, Ambrosio G, Ragni M, Pascucci I, Triggiani M, Oriente A, McNatt J, Buja LM, Condorelli M, Chiariello M, Willerson JT. Shrot-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation 1993; 88: 1205-14.
52. Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Platelets in biology and phatology. Gordon JL, eds. Elsevier/North-Holland biomedical Press, Amsterdam, 1976; pp 23-60.
53. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I a model of deep vessel injury. Influence of blood rheology, von Willebrand Factor and blood coagulation. Circulation 1988; 78: 1431-42.
54. Holst J, Lindblad B, Nordfang O, Ostergaard PB, Hedner U. Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?. Haemostasis 1996; 26: 23-30.
55. Valji K, Arun K, Bookstein JJ. Use of a direct thrombin inhibitor (agatroban) during pulse-spray thrombolysis in experimental thrombosis. J Vasc Interv Radiol 1995; 6: 91-5.
56. Maniatis T, Fritsch EF, Sambrook J. In : Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory, New York, NY 1982; pp 1-506.
57. Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions. Blood 1989; 73: 961-7.
58. Nichols TC, Bellinger DA, Tate DA, Reddick RL, Read MS, Koch GG, Brinkhous KM, Griggs TR. Von Willebrand factor and occlusive arterial thrombosis. Arteriosclerosis 1990; 10: 449-61.
59. Fuster V, Griggs TR. Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis. Prog Hemost Thromb 1986; 56: 159-83.
60. Fuster V, Bowie JW, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to atherosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978; 61: 722-30.
61. Badimon L, Steele P, Badimon JJ, Bowie EJW, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs. Arteriosclerosis 1985; 5: 366-70.
62. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemostasis 1995; 74: 552-9.
63. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 85: 1234-41.